Objectives To observe the effects of rosiglitazone on myocardial fibrosis of chronic myocardial ischaemia in dogs.
Methods 30 male healthy dogs of clean grade, were randomly divided into control group with 10 dogs, chronic myocardial ischaemia group with 10 dogs and rosiglitazone intervention group was 10 dogs. Dogs in Chronic myocardial ischaemia group and the rosiglitazone intervention group were injected 4% isoproterenol 50 mg everyday while dogs in control group were injected equal normal saline for eight weeks. Three weeks later, dogs in rosiglitazone intervention group were lavaged with rosiglitazone (3 mg/kg) everyday for four weeks. Dogs in the other groups were lavaged with equal normal saline. Immunohistochemical staining was used to detect the expressions of TNF-a and CX43 in myocardium of dogs and HE staining was used to detect the extent of myocardial fibrosis in dogs.
Results The extent of myocardial fibrosis and the expressions of TNF-a and CX43 were significantly higher in dogs of Chronic myocardial ischaemia group and rosiglitazone intervention group than in the control group and rosiglitazone intervention group were significantly lower than chronic myocardial ischaemia group.
Conclusions Rosiglitazone can reduce myocardial fibrosis of chronic myocardial ischaemia dogs and improve myocardial remodelling.